Moret_2010_Atherosclerosis_208_324

Reference

Title : Prevalence and function of anti-lipoprotein lipase auto-antibodies in type V hyperchylomicronemia - Moret_2010_Atherosclerosis_208_324
Author(s) : Moret M , Pruneta-Deloche V , Sassolas A , Marcais C , Moulin P
Ref : Atherosclerosis , 208 :324 , 2010
Abstract :

PURPOSE: Type V hyperlipidemia (HTG V) characterized by accumulation of both chylomicrons and VLDL results from a complex combination of genetic and environmental factors. However, a large proportion of sporadic cases remains largely unexplained. In a few cases, in a context of autoimmunity, auto-antibodies inhibiting lipoprotein lipase (LPL) activity have been incriminated. To establish their contribution to common type V hyperlipidemia in subjects with no apparent evidence of autoimmune background, we systematically screened the presence of these antibodies and their inhibition properties. METHODS: Screening for circulating anti-human LPL immunoglobulin G (anti-hLPL IgG) was carried out by western blotting in 63 subjects with HTG V and 77 controls. Inhibition of lipolytic activity by plasma from these patients was measured ex vivo. RESULTS: Anti-hLPL IgG was detectable in plasma from both controls and subjects with HTG V. After establishment of a threshold value corresponding to the 95th percentile of the control population, 27% of subjects with HTG V were found to have abnormal antibody levels (P<0.001). Only plasma obtained from these hyperchylomicronemic subjects with a high level of anti-hLPL IgG inhibited triglyceride hydrolysis whereas plasma from controls or HTG subjects with normal anti-hLPL IgG levels had no inhibitory effect (-13.5+/-3.4% vs 1.6+/-3.4%; P=0.04). However, no correlation was observed between anti-hLPL IgG levels, inhibitory effect and plasma triglyceride concentration. CONCLUSION: High levels of anti-hLPL immunoreactivity could be detected in only one out of four adult patients with type V hyperchylomicronemia. Furthermore, only a minority of these subjects (less than 10%) displayed both high anti-hLPL IgG levels and substantial inhibition (>20%) of plasma lipolysis. These auto-antibodies, in this setting only, might contribute to the occurrence of a minority of sporadic type V dyslipidemia cases.

PubMedSearch : Moret_2010_Atherosclerosis_208_324
PubMedID: 19695572

Related information

Citations formats

Moret M, Pruneta-Deloche V, Sassolas A, Marcais C, Moulin P (2010)
Prevalence and function of anti-lipoprotein lipase auto-antibodies in type V hyperchylomicronemia
Atherosclerosis 208 :324

Moret M, Pruneta-Deloche V, Sassolas A, Marcais C, Moulin P (2010)
Atherosclerosis 208 :324